RecruitingDelayed Graft FunctionDGFKidney Transplant
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Eligible age
18+ yrs
Accepts
All genders
Locations
23 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Sponsor: Alexion Pharmaceuticals, Inc.
You may qualify if…
- ✓ ≥ 18 years of age at the time of signing the informed consent
- ✓ Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)
- ✓ A candidate for kidney transplant from:
- ✓ 1. Donation after Circulatory Death (DCD) donor
- ✓ 2. High-risk Donation after Brain Death (DBD) donor
You may not qualify if…
- ✕ Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification
- ✕ Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06830798 · last updated 2026-06-18